Furthermore, a statistically significantly higher DTX concentration was only shown in tumor tissues for treatment at 2 and 16 h with the HER2-LsbMDDs respectively being 2.32 and 1.3-fold higher than the other three formulations. This evidence concerns the gene ERBB2 and neoplasm.